Astellas Venture Management LLC is the corporate venture capital arm of Astellas Pharma Inc., a global pharmaceutical company headquartered in Japan. Astellas Venture Management invests in emerging biotechnology companies dedicated to the development of new therapeutics and new drug discovery platform technologies. Astellas Venture Management is currently managing four funds totaling approximately $100 million and is based in Menlo Park, California, USA.
Hatteras Venture Partners is a venture capital firm based in Research Triangle Park, NC, USA, with a focus on biopharmaceuticals, medical devices, diagnostics, and related opportunities in human medicine. Founded in 2000, the firm consists of an experienced team with a broad and complementary skill set that is particularly relevant to building successful new biomedical companies. The Hatteras Venture Partners team brings operational experience, a successful track record, and a proven ability to enhance the value of the companies in which it invests. With four funds, the firm has more than $200 million under management.
Headland Ventures is an investment partnership focused on early-stage company investing. It is based in Sausalito, California, USA.
Intersouth Partners is one of the most active and experienced venture funds in the Southeast, having invested in more than 100 private companies over the last two decades. Founded in 1985, Intersouth manages $780 million in seven venture capital limited partnerships, making it the largest venture capital fund in North Carolina and one of the largest in the Southeast. Based in Durham, North Carolina, USA, Intersouth Partners seeks a broad range of investment opportunities in the technology and life sciences sectors.
Lilly Ventures, a stand-alone venture capital firm with its roots in the scientific tradition of Eli Lilly and Company, seeks to invest in great companies with compelling life science innovations and outstanding management teams in North America and Europe. The firm actively partners with management teams and co-investors of our portfolio companies at the seed, early and expansion stages. Lilly Ventures targets investments in biotechnology companies that leverage proprietary drug discovery or development technologies to build a multi-product pipeline that can have a meaningful impact on patient outcomes. Lilly Ventures is located in Indianapolis, Indiana, USA.
Lurie Holdings, Inc. manages investments for Ann Lurie and various Lurie family trusts for which Ms. Lurie is trustee. Lurie Holdings, LLC is based in Chicago, Illinois, USA.
The Novartis Option Fund is a $200 million fund that is part of the Novartis Venture Funds. Established in 1996, the Novartis Venture Funds currently manages over $700 million in committed capital and is invested in more than 65 private companies. The objective of the Novartis Option Fund is to seed innovative companies through initial and follow on investments. The Novartis Option Fund is located in Basel, Switzerland and Cambridge, Massachusetts, USA.